Molbio Diagnostics announced a robust Q1 FY27 performance with Rs 408 crore in revenue and a 25% EBITDA margin. Driven by its Truenat platform, the company saw 62.4 lakh test kits sold, which now account for 75% of total revenue. With a new two-year government TB diagnostic contract and a steady pipeline of 34 new assays, management maintains a positive growth outlook for the year. Shareholders should note the continued investment in R&D and the early-stage operational losses in its OptraScan subsidiary.
Molbio Diagnostics Q1 FY27 Financial Results
Revenue from operations reached Rs 408 crore; PAT stands at Rs 52.7 crore.
Reader Takeaway: Strong recurring revenue from test kits balances high R&D spend and early-stage subsidiary losses.
What just happened
Molbio Diagnostics reported a solid first quarter for FY27, generating Rs 408 crore in revenue. The company’s EBITDA came in at Rs 104 crore, representing a healthy 25% margin. A significant portion of this growth is attributed to the sale of 62.4 lakh test kits, which now constitute roughly 75% of the company's total revenue, showcasing the recurring nature of the Truenat platform.
Why this matters
The company’s business model relies on placing hardware and subsequently generating consistent revenue from consumables. With an installed base of 12,500 machines, Molbio is well-positioned to capitalize on the shift from traditional microscopy to molecular testing, especially in the TB diagnostics segment. The recent two-year government rate contract provides further visibility into future earnings.
R&D and Strategic Focus
Molbio is investing heavily in future growth, with Rs 72 crore allocated for automation and Rs 105 crore for a new integrated R&D center in Bangalore. The firm currently holds 207 patents and employs over 153 scientists. Its pipeline includes 34 new assays and expansion into 22 additional diseases, which is essential to long-term diversification beyond TB.
Subsidiary Performance
While the core business remains stable, the OptraScan subsidiary is currently in an early stage of development, reporting a Rs 9 crore loss this quarter. Despite this, management remains optimistic, especially following the US FDA clearance received in July 2026. The Prognosys digital X-ray unit continues to perform steadily, contributing Rs 154 crore in revenue for the previous fiscal year.
Risks to watch
Investors should monitor the company's heavy reliance on government funding cycles and tender renewals. Additionally, the continued drag from the OptraScan subsidiary may impact consolidated margins throughout FY27. Future profitability depends on successful scaling of new assays and sustained government support for molecular testing adoption.